Aposense, Glaxo align for PET tracer research
Aposense, a developer of agents targeting apoptosis for molecular imaging and therapy, has formed a collaboration with the London-based GlaxoSmithKline to evaluate the potential of Aposense's PET tracer ML-10 in monitoring drug activity in clinical studies of cancer therapies.
The project is intended to assess the contribution of ML-10 in accelerating clinical development of cancer therapies, according to the Petach-Tikva, Israel-based Aposense.
The initial term of the non-exclusive collaboration is for two years, and can be extended on certain conditions. Financial terms of the agreement were not disclosed.
The project is intended to assess the contribution of ML-10 in accelerating clinical development of cancer therapies, according to the Petach-Tikva, Israel-based Aposense.
The initial term of the non-exclusive collaboration is for two years, and can be extended on certain conditions. Financial terms of the agreement were not disclosed.